IL-10 is an immunoregulatory cytokine that can modulate immune processes, inhibiting the expression of inflammatory T h 1 type responses as well as affecting antigen-presenting cell function. In addition, IL-10 has been shown to be active at mucosal surfaces. In the present study, we examined the role of IL-10 on orally and nasally induced tolerance. Treatment of (PL/J ⍥ SJL)F 1 mice with low-dose oral myelin basic protein (MBP) (0.5 mg) and simultaneous oral IL-10 given 3 times reduced the severity and incidence of experimental autoimmune encephalomyelitis (EAE), whereas administration of oral IL-10 alone or MBP alone given in these doses had no effect. Lymphocytes from mice treated orally with MBP and IL-10 proliferated less, and produced decreased amounts of IFN-γ and IL-2 and increased amounts of IL-10 and transforming growth factor-β upon in vitro stimulation with MBP. Nasal administration of antigen and IL-10 reduced proliferative responses and IFN-γ production, increased IL-10 production, and enhanced protection from EAE. In addition, oral IL-10 combined with oral myelin oligodendrocyte glycoprotein (MOG) 35-55 reduced relapses in MOG-induced EAE in the NOD mouse, as well as enhanced the protective effect of oral insulin in the NOD model of diabetes. These results demonstrate that IL-10 is biologically active at mucosal surfaces and can act synergistically to enhance the tolerogenic effects of mucosally administered antigen.
Introduction
Oral and nasal administration of antigen have been shown to become IFN-γ-secreting T h 1 cells (8) . Activation of CD4 ϩ T cells in the presence of IL-10 leads to the induction of cells be effective in inhibiting experimental models of autoimmune disease in animals and oral tolerance is also being which do not proliferate well and produce large amounts of IL-10 plus transforming growth factor (TGF)-β, termed T r 1 tested for the treatment of human diseases (1). Oral tolerance is mediated by different mechanisms depending on the dose cells (9) . Seder et al. demonstrated that TGF-β promotes the differentiation of TGF-β-producing T h 3 cells (10) and we have of antigen fed. High doses favor clonal deletion (2) and anergy (3,4), whereas low doses favor the induction of active shown that culture of MBP TCR transgenic spleen cells in the presence of IL-4 results in an increased frequency of TGF-β-suppression (5) . Nasal administration of antigen also induces tolerance and suppresses experimental models of autosecreting cells as measured by limiting dilution analysis (11) . IFN-γ administration has been shown to inhibit (12) , immune disease in a number of systems (reviewed in 1). This route of administration has also been used to prime for local whereas anti-IL-12 treatment has been shown to enhance, oral tolerance and increase the secretion of TGF-β (13) and systemic immune responses (6) .
Cytokines play an important role in T cell differentiation and suggesting that in vivo, low-dose oral tolerance may be favored by factors which enhance the induction of regulatory direct precursor T cells (T h p) toward T h 1, T h 2, T h 3 or T r 1 lineages. IL-4 directs precursor T cells to become IL-4-cells or inhibit T h 1 responses. Cytokine-induced immune deviation has been investigated secreting T h 2 cells (7) , whereas IL-12 directs T h 0 cells to as potential therapy for T h 1-type autoimmune diseases, as Diego, CA): purified rat anti-mouse IL-2 (clone JES-1A12), IL-4 (clone BVD4-1D11), IL-10 (clone JESS-2A5) and IFN-γ cytokine present at time of activation may alter the pathogenicity of effector T cells (14) . However, there may be side (clone R4-6A2) mAb; biotinylated rat anti-mouse IL-2 (clone JES6-5H4), IL-4 (clone BVD6-24G2), IL-10 (clone SXC-1) and effects of systemically administered cytokines, which may limit their use. Accumulating evidence suggests that oral IFN-γ (clone XMG1.2); and recombinant mouse IL-2 (rIL-2), IL-4, IL-10 and IFN-γ. For oral and nasal IL-10 experiments, administered cytokines are biologically active and may avoid the deleterious effects of systemic cytokine administration recombinant murine IL-10 was a kind gift of the Schering Plough Research Institute (Kenilworth, NJ). (15) . Both oral and nasal routes of cytokine administration have been found to be biologically active including IL-4, IL-6, IL-10, IFN and TGF-β (11, (16) (17) (18) (19) .
Oral administration of autoantigens and of IL-10 Systemic administration of IL-10 has been tested in the (PL/JϫSJL)F 1 mice were fed with 0.5 mg of OVA as a experimental autoimmune encephalomyelitis (EAE) model control protein, 0.5 mg of MBP and/or 0.1, 1 or 10 µg of with differing results. Administration of IL-10 during the IL-10 dissolved in 0.25 ml PBS by gastric intubation with an inductive phase of disease was reported to suppress 18-gauge stainless steel feeding needle (Thomas Scientific, actively induced acute EAE in the Lewis rat (20) , whereas Swedesboro, NJ). Animals were fed 3 times, every other day IL-10 not only failed to abrogate chronic relapsing EAE in an over a total of 5 days and immunized 2 days following the adoptively transferred model of disease in SJL/J mice but last feeding. NOD mice were fed with 250 µg of insulin B exacerbated disease (21) . Nasal administration of IL-10 was chain peptide 4 times in the first week beginning at age 3-4 reported to suppress the clinical signs of acute EAE in Lewis weeks and then once a week. Oral IL-10 (1 µg) was given rat and prevented relapses of protracted disease in DA rats alone or at the time of B chain peptide administration. For (19) . IL-10 is important for mucosal immune responses as MOG-induced EAE in the NOD mouse, 250 µg MOG 35-55 IL-10-deficient animals develop chronic inflammatory bowel peptide and/or 1 µg IL-10 was given orally every day for 4 disease that shares histopathological features with human days prior to immunization. disease (22) .
In the present study, we investigated the effect of mucosally Nasal administration of MBP and of IL-10 administered IL-10 when low doses of antigen were orally or nasally administered. To determine whether IL-10 acts Mice were treated nasally 3 times with 0.5 µg of MBP and/or 1 µg IL-10 dissolved in 0.01 ml PBS (5 µl/nostril). synergistically, we have used an antigen dose we have previously described (11) as a suboptimal tolerizing regimen. We found that IL-10 acts synergistically to enhance low-dose Induction and clinical evaluation of EAE and diabetes oral tolerance in vivo in the EAE model and enhances the (PL/JϫSJL)F 1 mice received a s.c. injection in the flank of production of IL-10 itself in vitro. In addition, oral IL-10 100 µg of mouse MBP in 0. For proliferation and cytokine assays, cells from similarly treated mice were pooled and were cultured in 96-well plates peptide 10-24 were prepared using a peptide synthesizer and purified by HPLC (QCB, Hopkinton, MA). Ovalbumin at 5ϫ10 6 and 10ϫ10 6 cells/ml respectively in serum-free medium, X-VIVO 20 (Biowhittaker, Walkersville, MD). To (OVA) was purchased from Sigma (St Louis, MO). Polyclonal chicken anti-TGF-β1 antibody, human purified TGF-β1 and measure cytokines, culture supernatants were collected at 24 h for IL-2 and IL-4, 40 h for IL-10 and IFN-γ, and monoclonal mouse anti-TGF-β antibody (Clone 1D11) were purchased from R & D Systems (Minneapolis, MN). The at 72 h for TGF-β. For proliferation, cells were pulsed with [ 3 H]thymidine at 72 h and radioactivity determined 16 h later. following reagents were purchased from PharMingen (San (0.5 mg) or MBP (0.5 mg) and IL-10 (0.1, 1 or 10 µg) and immunized as described in Fig. 1 . Ten days after immunization, popliteal LNC were cultured at 1ϫ10 6 cells/well with 50 µg/ml of MBP in 0.2 ml of medium. Cytokine production was determined as described in
ELISA for cytokines
Methods. *Significant differences as described in Results.
Significance was determined by ANOVA as described in Methods.
Quantitative ELISA for IL-2, IL-4, IL-10 and IFN-γ were performed using paired mAb specific for corresponding cytokines per manufacturer's recommendations (PharMingen). TGF-β was determined as previously described (11). or IL-10 alone suppressed IL-2 production compared to OVA-fed mice. However, the combination of MBP plus IL-10 Statistical analysis led to a complete abrogation of IL-2 production (P Ͻ 0.0001). Maximum disease scores, day of disease onset, cytokine For IFN-γ production, enhanced suppression was also concentrations and thymidine incorporation were analyzed observed in animals treated with IL-10 plus MBP (P Ͻ 0.0001, by Student's t-test, ANOVA, χ 2 or non-parametric analysis. affect the disease model EAE. Animals were fed MBP 3 times at a dose that we have previously shown is not protective As shown in Fig. 1 , almost complete suppression of MBPspecific proliferation was observed in LNC from mice treated against EAE and 1 µg IL-10 was given orally at the time of each feeding. Three feedings of MBP at a dose of 0.5 mg with MBP plus IL-10 at all doses compared to those fed OVA (P Ͻ 0.001), IL-10 alone (P Ͻ 0.05) or MBP alone (P Ͻ 0.001).
per feeding or 1 µg IL-10 alone had no protective effect against onset, incidence or severity of EAE (Table 1) . However, Mice that received IL-10 alone also showed significantly less proliferation compared to mice fed with OVA (P Ͻ 0.001).
when MBP and IL-10 were given together, there was suppression of EAE severity (P ϭ 0.019, IL-10 ϩ MBP versus OVA; Similar results were also observed in splenocytes and when cultures were stimulated in vitro with MBP Ac1-11. P ϭ 0.036, IL-10 ϩ MBP versus MBP alone) (Table 1) . Disease incidence was also significantly decreased in mice fed with Cytokine secretion pattern of LNC is altered in animals treated a subtolerogenic dose of MBP plus IL-10 compared to those with MBP plus oral IL-10 receiving OVA alone (P ϭ 0.04) ( Table 1 ). The course of disease was also altered with oral MBP plus IL-10 decreasWe then tested the effect of oral IL-10 plus MBP on cytokine secretion. As shown in Fig. 2(A) oral administration of MBP ing the disease burden in mice (Fig. 3) . Although we observed IL-2 and IFN-γ secretion (Figs 1 and 2) no effect of 0.1 µg IL-10 plus MBP treatment was seen upon disease (Table 1) .
Oral IL-10 suppresses relapses in MOG-induced EAE Nasal administration of MBP and IL-10
Having observed that oral IL-10 acts synergistically with MBP to suppress MBP-induced EAE, we tested the effect of A number of reports have suggested that nasal administration of antigen is effective in inducing tolerance (reviewed oral IL-10 on relapses in MOG-induced EAE. NOD mice which develop relapsing EAE upon immunization with MOG 35-55 in 1). We therefore tested whether nasal administration of antigen plus IL-10 would enhance tolerance induced via this were fed 250 µg MOG peptide 4 times on consecutive days and 1 µg IL-10 was given orally at the time of each route. As shown in Fig. 5(A) , nasal administration of MBP and IL-10 enhanced suppression of IFN-γ production (P Ͻ 0.05). MOG feeding. Feeding MOG alone or MOG in combination with IL-10 had no protective effect on the first attack of EAE Conversely, IL-10 production was significantly augmented by combined nasal treatment with MBP plus IL-10 (P Ͻ 0.05) (day [12] [13] [14] . However, at the time of the first relapse (day 28-30) animals fed MOG peptide or MOG peptide with IL-10 compared to OVA or MBP alone (Fig. 5B) ; however, no increase in TGF-β was observed. This treatment was manifested a protective effect (Fig. 4) . Whereas MOG feeding alone reduced the severity of the clinical score, the oral also moderately successful at suppressing EAE (Fig. 6) . Interestingly, increasing doses of nasally administered MBP administration of MOG with IL-10 completely inhibited the second attack (P Ͻ 0.04). Interestingly, IL-10 given orally appeared to exacerbate disease; however, regardless of the dose of MBP, co-administration of IL-10 overcame the priming alone increased disease severity as previously reported in an adoptive transfer model of relapsing EAE in SJL/J mice (21) .
effect of MBP and suppressed disease (data not shown), age, 78% of the mice fed with OVA became diabetic. Fifty percent of mice fed with IL-10 and 40% of mice fed with B chain 10-24 were diabetic at 32 weeks of age. However, in the group fed with the combination of IL-10 and B chain 10-24, only 20% of the mice became diabetic (P Ͻ 0.02). As suggesting IL-10 may be acting to suppress mucosal priming via the nasal route. in the EAE model IL-10 feeding further enhanced the protective effect of oral insulin in inhibiting diabetes development. Oral IL-10 enhances suppression of diabetes by oral insulin in the NOD mouse Discussion As we observed that oral IL-10 acts synergistically with MOG to enhance suppression of relapsing EAE in NOD mice, we
In the present study we demonstrate that oral administration of IL-10 enhances the production of IL-10 and TGF-β generated investigated whether oral IL-10 could enhance the effect of oral insulin in inhibiting spontaneous diabetes development in by feeding MBP or MOG 35-55, and that this combination of oral IL-10 and oral autoantigens suppresses EAE. Nasal the NOD mouse. Three-week-old female NOD mice were fed 4 times on consecutive days with either OVA, 250 µg insulin administration of MBP and IL-10 enhances tolerance by decreasing IFN-γ and increasing IL-10 production as well B chain 10-24, 1 µg IL-10 or B chain 10-24 with IL-10. For the duration of the experiment mice were fed once a week as suppressing EAE. Furthermore, oral IL-10 enhances the suppression of diabetes in the NOD mouse treated with with IL-10, B chain 10-24 or both.
Three mice of each treatment group were immunized with oral insulin. One of the mechanisms by which oral tolerance is mediated insulin B chain 10-24, 2 days after the last of the four feedings in order to check the cytokine profile of lymphocytes involves the generation of regulatory cells including T h 2, T h 3 and T r 1 cells. These cells are preferentially generated when from the immunized mice upon in vitro stimulation with the immunizing antigen. The data in Fig. 7 describe the marked low doses of antigen are fed (24). The factors which influence the generation of these cells, and the relationship of T h 3/T r 1 decrease of IL-2 (P Ͻ 0.05) and IFN-γ (P Ͻ 0.02) secretion in LNC harvested from mice fed with IL-10 in combination cells to cells which secrete T h 1 (IFN-γ)-and T h 2 (IL-4)-type cytokines has not yet been well defined. Given that low-dose with insulin B chain 10-24. Mice fed with either IL-10 or B chain 10-24 alone showed a decreased T h 1 response as oral tolerance involves the induction of cells that actively suppress T h 1-type responses, factors which favor the inducwell; however, IL-2 and IFN-γ secretion was completely abrogated in lymphocytes from mice fed with the combination tion of regulatory T h 2/T h 3/T r 1-type cells would be expected to enhance low-dose oral tolerance. This is consistent with of IL-10 and insulin. Increase in TGF-β secretion was observed only in the group fed with the combination of our previous findings that IL-4 enhanced the protection of oral MBP in the EAE model when suboptimal doses of MBP insulin and IL-10 (P Ͻ 0.004) compared to all other treatment groups. IL-10 production was up-regulated in both the B were fed (11), and with the findings of others that IFN-γ inhibits . Two days after the last feeding, mice were immunized with 100 µg of insulin B chain 10-24 emulsified in CFA in the hind footpads. Ten days after immunization, popliteal LNC were stimulated in culture at 10ϫ10 6 cells/ml for cytokine assays with 100 µg/ml of insulin peptide in 0.2 ml medium. Cytokine production was determined as described in Methods. Data represent mean Ϯ SD of duplicate cultures. *Significant differences as described in Results. Results are representative of three similar experiments.
reported to enhance oral tolerance, and include coupling of antigen to the B subunit of cholera toxin (29) or the use of multiple emulsions as an adjuvant (30) . Different mechanisms of oral tolerance may be induced depending on the amount fed with high dose favoring deletion/anergy (2-4) and low dose favoring active suppression (5) . In the present study we have shown the effect of oral IL-10 on low-dose oral tolerance. Aroeira et al. reported that anti-IL-10 antibodies did not affect high-dose oral tolerance (31) , which is consistent with data we have obtained that oral IL-10 does not enhance oral tolerance when large doses of OVA (20 mg) are fed (A. J. Slavin, unpublished). Although it is unexpected that an orally administered cyto- responses in the gut as measured by IFN-γ message in the Peyer's patches and this protective effect was reversed by the administration of anti-TGF-β antibody (11) . Oral IFN-β (25) and anti-IL-12 enhances (13) oral tolerance. We and synergizes with the induction of oral tolerance in mice fed others (26-28) have also shown that i.p. or oral administration low-dose MBP (17) . Oral IFN α/β (type I) can suppress of the T h 2-inducing schistosomiasis soluble egg antigen in development of collagen-induced arthritis, and in a doseboth EAE and diabetes suppresses T h 1 and enhances T h 2 dependent manner reduce delayed-type hypersensitivity, (IL-10 and IL-4) cytokine responses to the autoantigens erythema and edema (32). Similarly Type I IFN can reduce involved in disease as well as improves disease outcome.
the severity of EAE (33) as does orally administered IFN-γ Factors which act as mucosal adjuvants and thus enhance (16) . By contrast, nasal administration of IFN-γ can abrogate tolerance induced nasally with AChR in an experimental the induction of gut immune responses have also been model of myasthenia gravis (EAMG) (18) . These combination preventing degradation and increasing pinocytosis by epithelium. Given the amount (1 µg) we are feeding, if only therapies provide for the use of less tolerizing antigen, reducing exposure to autoantigen and decreasing the likeli-0.1% is not degraded the amount of IL-10 is in the nanogram range, which is physiologically relevant. Furthermore, expohood of developing autoantibodies or adverse immune responses to the tolerizing antigen.
sure to digestive enzymes does not necessarily abrogate bioactivity as IL-6 retains bioactivity following treatment with Nasal administration of autoantigen to suppress autoimmune diseases is advantageous as relatively minute trypsin chymotrypsin for 30 min (15) . Another possibility is that by traversing the epithelium IL-10 influences local antigen amounts are necessary. Intranasal administration of antigen has been used in several experimental models of autoimmune presentation where regulatory cells are being generated. For example, the presence of dendritic cells in the airway disease. Nasal application of retinal proteins can suppress EAU (34) In summary, we have found that mucosally administered IL-10 can suppress T h 1 responses and enhance production that was necessary for the induction of oral tolerance and protection from EAMG (42) . In this model it appears that nasal of TGF-β/IL-10 when given with autoantigen, both in the EAE model and the NOD model of diabetes. Our results and those tolerance to EAMG is mediated by TGF-β (43) and nasal administration of IFN-γ at the time of AChR administration of others (15) suggest that in vivo administration of IL-10 enhances the effectiveness of oral tolerance for the treatment abrogates the protective effect of nasal AChR, although IFN-γ by itself does not alter the outcome of EAMG.
of autoimmune diseases and may ultimately be applied to human diseases in which oral tolerance is currently being IL-10 has been used in the treatment of many disease models with varying results. IL-10 has been shown to tested as a therapeutic modality. augment humoral immune responses and inhibit certain aspects of cellular immunity (44) . IL-10 mRNA was seen tothe development of EAE (46) . Nasal IL-10 prevented relapses in protracted disease in DA rats (19) and suppressed acute EAE in Lewis rat but s.c. administration did not (47 
